KAT-101 is under clinical development by NewG Lab Pharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KAT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KAT-101 overview

KAT-101 is under development for the treatment of metastatic hepatocellular carcinoma, bladder cancer, melanoma, pancreatic cancer, and leukemia. The therapeutic candidate is a derivative of 3 bromopyruvic acid. It acts by targeting GAPDH. It is administered through oral route.

NewG Lab Pharma overview

NewGLab Pharma Co Ltd (NewGLab) specializes in the production and distribution of pharmaceuticals and biologics. NewGLab is headquartered in Bucheon, South Korea.

For a complete picture of KAT-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.